Related Experiment Videos
Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients
1University of Texas Medical School, Houston 77030, USA.
Transplantation Proceedings
|September 2, 1998
Summary
Rapamycin (RAPA) enhances calcineurin inhibitor therapy, reducing acute rejection and potentially chronic rejection. This allows for lower calcineurin inhibitor doses and corticosteroid withdrawal, though side effects like myelosuppression and hyperlipidemia require further study.
Area of Science:
- Transplantation immunology
- Pharmacology
Background:
- Calcineurin inhibitors (e.g., cyclosporine [CyA]) are standard immunosuppressants.
- Acute and chronic rejection remain significant challenges in organ transplantation.
- Corticosteroids are widely used but associated with adverse effects.
Purpose of the Study:
- To evaluate the potential of Rapamycin (RAPA) as an addition to maintenance immunosuppression.
- To assess RAPA's efficacy in preventing and treating acute and chronic rejection.
- To explore RAPA's role in mitigating nephrotoxicity and corticosteroid-related side effects.
Main Methods:
- Review of existing data from in vitro and in vivo model systems.
- Analysis of clinical observations regarding RAPA's impact on rejection episodes.
- Assessment of potential benefits for reducing CyA and corticosteroid doses.
Main Results:
- RAPA appears to potentiate CyA-based therapy, significantly improving immunosuppression.
- RAPA reduces acute rejection incidence and may disrupt steroid- and antibody-resistant rejection.
- Preliminary data suggest RAPA may offer prophylaxis against chronic rejection.
Conclusions:
- RAPA is a promising candidate for maintenance immunosuppression, enhancing current therapies.
- RAPA may enable reduced CyA doses, mitigating nephrotoxicity, and corticosteroid withdrawal, reducing associated morbidities.
- Further research is needed to understand and manage RAPA's adverse effects, such as myelosuppression and hyperlipidemia.